FDA Inspection 961421 — Central Pennsylvania Blood Bank Headquarters
The FDA completed an inspection of Central Pennsylvania Blood Bank Headquarters on Feb 26, 2016 in Hummelstown, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 26, 2016
- Fiscal Year
- 2016
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Hummelstown, PA (United States)